BetterLife Obtains TD-0148A Behavioural Pharmacology Data Confirming its Projected Non-hallucinogenic Property
VANCOUVER, British Columbia, Nov. 16, 2021 (GLOBE NEWSWIRE) — BetterLife Pharma Inc. (“BetterLife” or the…
VANCOUVER, British Columbia, Nov. 16, 2021 (GLOBE NEWSWIRE) — BetterLife Pharma Inc. (“BetterLife” or the…
OREM, Utah., Nov. 16, 2021 (GLOBE NEWSWIRE) — Reflect Scientific, Inc. (OTCQB: RSCF), a provider…
Study demonstrates oral vaccination significantly reduces viral titers in the lung and protects against COVID-19…
Takeda Pharmaceuticals Company (“Takeda”), a global, values-based, R&D-driven biopharmaceutical company, hosted the formal inauguration of…
NEW YORK and CLEVELAND, Nov. 16, 2021 (GLOBE NEWSWIRE) — Abeona Therapeutics Inc. (Nasdaq: ABEO),…
—To Launch Phase 2/3 Smoking Cessation Clinical Trial with Johns Hopkins University (JHU) Signed 5-Year…
SAN DIEGO, Nov. 16, 2021 (GLOBE NEWSWIRE) — Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated…
NEW YORK, Nov. 16, 2021 (GLOBE NEWSWIRE) — Tilray, Inc. (“Tilray”) (Nasdaq: TLRY; TSX: TLRY),…
— Patency and host cell remodeling of the HAV were observed in all study implants…
MILAN, Italy and NEW YORK, Nov. 16, 2021 (GLOBE NEWSWIRE) — Genenta Science, a clinical-stage biotechnology…
Investigational therapeutics injected via the SCS Microinjector® demonstrate positive clinical data in wet AMD, diabetic…
Interim data update at SITC for ongoing ACTengine® IMA203 trial targeting PRAME demonstrated clinical responses…
CAMBRIDGE, Mass., Nov. 16, 2021 (GLOBE NEWSWIRE) — Voyager Therapeutics, Inc. (Nasdaq: VYGR), a gene…
Positive trend observed in transfusion-dependent subjects treated with higher dose tovinontrine for reduced transfusion burden Tovinontrine…
ADMA Now Collects Plasma from Six Vertically Integrated Centers with Three Additional Facilities Under Construction…
OCALA, Fla., Nov. 16, 2021 (GLOBE NEWSWIRE) — AIM ImmunoTech Inc. (NYSE American: AIM) announces…
VASCEPA/VAZKEPA found in prespecified and post hoc analyses to reduce total ischemic events by 32%…
Company is Scheduled to Conduct Pre-IND Meeting with the U.S. FDA Later This Month and Potentially Initiate…
Third Quarter Revenues of $6.4 Million; Year-to-Date 2021 Revenues Increased 21% Clarity on Regulatory Pathway…
NEW YORK, Nov. 16, 2021 (GLOBE NEWSWIRE) — IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical…